Temple OrthoBiologics is developing TX-33, an intra-articular drug treatment designed to prevent scar tissue formation following orthopedic injury or surgery. This novel therapeutic aims to mitigate post-operative complications and improve patient recovery outcomes. The company focuses on advancing pharmaceutical solutions within sports medicine and orthopedics.
Funding
Funding not disclosed
Founders
Product
Problem
Following joint or muscle injury or surgery, the body's natural healing response can lead to excessive scar tissue formation (arthrofibrosis), resulting in stiffness, limited range of motion, pain, and long-term joint degeneration. Current treatments lack effective pharmaceutical options to prevent this post-operative fibrosis.
Solution
Temple OrthoBiologics is developing TX-33, an intra-articular drug treatment designed to prevent scar tissue formation following joint injury or surgery. TX-33 combines advanced biomaterials with a pharmaceutical-grade derivative of a molecule known for promoting muscle recovery. The injectable solution is administered within a specific therapeutic window to activate innate healing mechanisms, promoting normal tissue repair instead of scar tissue development. The advanced biomaterials are engineered to release the active molecule locally in a controlled and targeted manner, improving outcomes and minimizing potential systemic side effects. By addressing biological processes as an early intervention strategy, TX-33 aims to minimize or prevent arthrofibrosis, enhancing recovery when combined with physical therapy and rehabilitation.
Target Audience
The primary target audience includes athletes, active individuals, and patients undergoing joint or muscle surgery, as well as orthopedic surgeons and sports medicine clinicians seeking to improve patient outcomes and accelerate recovery.
Features
- Intra-articular injection administered within a specific therapeutic window post-injury or surgery.
- Combination of advanced biomaterials and a pharmaceutical-grade molecule derivative.
- Designed to activate innate healing mechanisms for normal tissue repair.
- Engineered for controlled, precise, and targeted release of the active molecule.
- Aims to delay or halt key molecular events leading to scar tissue formation.
- Designed to minimize potential systemic side effects.